BioNTech SE (BNTX)
BioNTech develops immunotherapies for cancer and infectious diseases and sells the COVID-19 vaccine Comirnaty. It last closed at $84.86 on Nov 17, down 0.47% on the day. The average 12-month price target from 7 analysts is $116.14 (+36.9% from the last close), with a high of $132.00 and a low of $105.00. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (6 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in BNTX, 50% of them bullish and 50% bearish. In the past 30 days there were 2 dark pool prints totaling $1.8M, the largest $937K.
Key Stats
Fiscal 2025Not reported for this period.
From BNTX's SEC filings, latest 20-F/A for the period ending Dec 31, 2025 (filed Jul 30). Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 7 analysts who set a price target on BNTX in the past 90 days. The average target is $116.14, with a high of $132.00 and a low of $105.00, compared with the last close of $84.86.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 9 | HC Wainwright & Co. | Maintained | Buy | $110 |
| Nov 4 | UBS | Target lowered | Buy | $135 → $125 |
| Nov 4 | Morgan Stanley | Target lowered | Buy | $114 → $106 |
| Nov 4 | Wells Fargo | Maintained | Buy | $125 |
| Nov 4 | Evercore ISI Group | Target lowered | Buy | $130 → $110 |
Technical Analysis
The stock is 3% below its 20 day and 9% below its 50 day average. It is 13% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 39). The nearest support is the Pivot S1 at $84.32, and the nearest resistance the Pivot at $84.92.
| RSI (14) | 38.88 | Weak, oversold below 30 | Neutral |
| MACD | -1.97 | Above its signal line | Bullish |
| Stochastic | 14.6 | Near the bottom of its range | Oversold |
| ADX (14) | 15.5 | No clear trend | |
| Williams %R | -90.7 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -141.4 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −2.4% | Change over 10 sessions | Bearish |
| ATR (14) | $2.61 | Typical daily range, 3.1% of price |
| RSI (14) | 40.41 | Middle of its range | Neutral |
| MACD | -2.70 | Below its signal line | Bearish |
| Stochastic | 4.4 | Near the bottom of its range | Oversold |
| ADX (14) | 14.2 | No clear trend | |
| Williams %R | -98.1 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -111.2 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −12.3% | Change over 10 sessions | Bearish |
| ATR (14) | $7.34 | Typical daily range, 8.7% of price |
What happened before
See how BNTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How BNTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.
Whale Options Flow
90DNo whale options trades in BNTX in the last 90 days.
Dark Pool
30DBNTX Institutional Ownership
Full report →- ▲145 buying vs 126 selling
- ●Shares held by funds -0.2%
- ▲Funds holding +18
- ▲Superinvestors: 3 added, 1 cut
- ▲Put/call 1.05 to 0.20
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 302 | 284 | +6.3% |
| In funds' top 10 | 5 | 5 | 0.0% |
| Held by funds | – | – | – |
| New / increased | 56 / 89 | 39 / 92 | +10.7% |
| Reduced / sold out | 89 / 37 | 71 / 30 | +24.8% |
| Put/call ratio | 0.20 | 1.05 | −80.7% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BNTX is in one of them and how their past BNTX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered BNTX in an article yet. Here's the latest on the wider market.
BNTX Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Valerie HoyleD · OR | Sell | $1K – $15K | Aug 7, 2025 | Sep 12, 2025 | 36 d |
| Josh GottheimerD · NJ | Sell | $1K – $15K | Sep 3, 2024 | Oct 3, 2024 | 30 d |
| Josh GottheimerD · NJ | Sell (partial) | $1K – $15K | Aug 30, 2024 | Sep 11, 2024 | 12 d |
| Josh GottheimerD · NJ | Buy | $1K – $15K | Apr 15, 2024 | May 15, 2024 | 30 d |
| Josh GottheimerD · NJ | Sell | $1K – $15K | Mar 14, 2024 | Apr 7, 2024 | 24 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About BioNTech SE
BioNTech is a biotechnology company based in Mainz, Germany, that develops medicines based on the immune system. Its main focus is cancer, with further work on vaccines and therapies for infectious diseases, using messenger RNA and protein-based technologies. Its marketed product is Comirnaty, a COVID-19 vaccine sold through partners such as Pfizer and Fosun Pharma in many countries. Its customers are mainly public health authorities and healthcare systems that buy vaccines. Most of its other products are still being tested in clinical trials.
- Headquarters
- Mainz, Germany
- Founded
- 2008
- Website
- biontech.de ↗






